MoonLake Immunotherapeutics (MLTX)

Market Cap	980.67M
Revenue (ttm)	n/a
Net Income (ttm)	-210.50M
Shares Out	71.37M
EPS (ttm)	-3.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	916,532
Open	13.37
Previous Close	13.49
Day's Range	13.32 - 14.02
52-Week Range	5.95 - 62.75
Beta	1.21
Analysts	Buy
Price Target	36.33 (+164.41%)
Earnings Date	Nov 5, 2025

About MLTX

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: MLTX
• Website: https://www.moonlaketx.com

Analyst Summary

According to 9 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price target is $36.33, which is an increase of 164.41% from the latest price.

Price Target

$36.33

(164.41% upside)

Analyst Consensus: Buy